1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        Europe Non-Alcoholic Steatohepatitis Market – By Product

1.3.2        Europe lobal Non-Alcoholic Steatohepatitis Market – By Application

1.3.3        Europe Non-Alcoholic Steatohepatitis Market – By Sales Channel

1.3.4        Europe Non-Alcoholic Steatohepatitis Market – By Country

2.           Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Europe Non-Alcoholic Steatohepatitis Market – Market Landscape

4.1         Overview

4.2         PEST Analysis

4.2.1        Europe PEST Analysis

4.3         Experts Opinion

5.           Europe Non-alcoholic steatohepatitis (NASH) Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Rising Prevalence of NASH

5.1.2        Increasing Initiatives for the Awareness of NASH

5.2         Market Restraints

5.2.1        Lack of Established Guidelines in the Diagnosis and Management of NASH

5.2.2        Withdrawal of Drugs from Seeking Marketing Authorization for NASH

5.3         Market Opportunities

5.3.1        Growing Opportunities in Developing Nations

5.3.2        High Competition among Market Players to Manufacture the First Marketed NASH Drug Creates Global Sales Opportunity

5.4         Future Trends

5.4.1        Growing Clinical Trials Involving Combination Studies of Drugs

5.5         Impact Analysis

6.           Non-alcoholic steatohepatitis (NASH) Market–Europe Analysis

6.1         Europe Non-Alcoholic Steatohepatitis Market Revenue Forecast and Analysis

7.           Europe Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts To 2028– by Product

7.1         Overview

7.2         Product Market Revenue and Forecast Analysis (US$ Mn)

7.3         Vitamin E and Pioglitazone

7.3.1        Overview

7.3.2        Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

7.4         Ocaliva

7.4.1        Overview

7.4.2        Ocaliva Revenue and Forecast to 2028 (US$ Mn)

7.5         Elafibranor

7.5.1        Overview

7.5.2        Elafibranor Revenue and Forecast to 2028 (US$ Mn)

7.6         Selonsertib & Cenicriviroc

7.6.1        Overview

7.6.2        Selonsertib Revenue and Forecast to 2028 (US$ Mn)

7.7         Others

7.7.1        Overview

7.7.2        Others Revenue and Forecast to 2028 (US$ Mn)

8.           Europe Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Application

8.1         Overview

8.2         Application Market Revenue and Forecast Analysis (US$ Mn)

8.3         Treatment

8.3.1        Overview

8.3.2        Treatment Market Revenue and Forecast to 2028 (US$ Mn)

8.4         Diagnosis

8.4.1        Overview

8.4.2        Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

9.           Europe Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2028 – by Sales Channel

9.1         Overview

9.2         Sales Channel Market Revenue and Forecast Analysis (US$ Mn)

9.3         Hospital Pharmacy

9.3.1        Overview

9.3.2        Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.4         Retail Pharmacy

9.4.1        Overview

9.4.2        Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

9.5         Online Provider

9.5.1        Overview

9.5.2        Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

10.        Europe Non-alcoholic steatohepatitis (NASH) Market Revenue and Forecasts to 2028 – Country Analysis

10.1      Europe: Non-alcoholic steatohepatitis (NASH) Market

10.1.1     Overview

10.1.3     Europe: Non-alcoholic steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

10.1.3.1       Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.1.1       Overview

10.1.3.1.2       Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.1.3       Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.1.4       Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.1.5       Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.1.3.2       France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.2.1       Overview

10.1.3.2.2       France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.2.3       France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.2.4       France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.2.5       France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.1.3.3       UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.3.1       Overview

10.1.3.3.2       UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.3.3       UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.3.4       UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.3.5       UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.1.3.4       Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.4.1       Overview

10.1.3.4.2       Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.4.3       Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.4.4       Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.4.5       Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.1.3.5       Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.5.1       Overview

10.1.3.5.2       Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.5.3       Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.5.4       Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.5.5       Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

10.1.3.6       Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.6.1       Overview

10.1.3.6.2       Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

10.1.3.6.3       Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

10.1.3.6.4       Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

10.1.3.6.5       Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

11.        Industry Landscape

11.1      Overview

11.2      Organic Developments

11.2.1     Overview

11.3      Inorganic Developments

11.3.1     Overview

12.        Company Profiles

12.1      Cadila Pharmaceuticals Ltd.

12.1.1     Key Facts

12.1.2     Business Description

12.1.3     Products and Services

12.1.4     Financial Overview

12.1.5     SWOT Analysis

12.1.6     Key Developments

12.2      Intercept Pharmaceuticals, Inc

12.2.1     Key Facts

12.2.2     Business Description

12.2.3     Products and Services

12.2.4     Financial Overview

12.2.5     SWOT Analysis

12.2.6     Key Developments

12.3      Novartis AG

12.3.1     Key Facts

12.3.2     Business Description

12.3.3     Products and Services

12.3.4     Financial Overview

12.3.5     SWOT Analysis

12.3.6     Key Developments

12.4      Galmed Pharmaceuticals.

12.4.1     Key Facts

12.4.2     Business Description

12.4.3     Products and Services

12.4.4     Financial Overview

12.4.5     SWOT Analysis

12.4.6     Key Developments

12.5      GENFIT.

12.5.1     Key Facts

12.5.2     Business Description

12.5.3     Products and Services

12.5.4     Financial Overview

12.5.5     SWOT Analysis

12.5.6     Key Developments

12.6      ONE WAY LIVER, S.L

12.6.1     Key Facts

12.6.2     Business Description

12.6.3     Products and Services

12.6.4     Financial Overview

12.6.5     SWOT Analysis

12.6.6     Key Developments

12.7      BioPredictive S.A.S

12.7.1     Key Facts

12.7.2     Business Description

12.7.3     Products and Services

12.7.4     Financial Overview

12.7.5     SWOT Analysis

12.7.6     Key Developments

12.8      Siemens Healthineers AG

12.8.1     Key Facts

12.8.2     Business Description

12.8.3     Products and Services

12.8.4     Financial Overview

12.8.5     SWOT Analysis

12.8.6     Key Developments

12.9      Laboratory Corporation of America Holdings

12.9.1     Key Facts

12.9.2     Business Description

12.9.3     Products and Services

12.9.4     Financial Overview

12.9.5     SWOT Analysis

12.9.6     Key Developments

13.        Appendix

13.1      About The Insight Partners

13.2      Glossary of Terms

LIST OF TABLES

Table 1.             Germany: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 2.             Germany: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 3.             Germany: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 4.             France: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 5.             France: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 6.             France: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 7.             UK: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 8.             UK: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 9.             UK: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 10.          Italy: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 11.          Italy: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 12.          Italy: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 13.          Spain: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Spain: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 15.          Spain: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 16.          Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Product – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Application– Revenue and Forecast to 2028 (US$ Million)

Table 18.          Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market, by Sales Channel – Revenue and Forecast to 2028 (US$ Million)

Table 19.          Organic Developments Done By Companies

Table 20.          Inorganic Developments Done By Companies

Table 21.          Glossary of Terms

LIST OF FIGURES

Figure 1.           Europe Non-Alcoholic Steatohepatitis Market Segmentation

Figure 2.           Europe Non-Alcoholic Steatohepatitis Market, By Country

Figure 3.           Europe Non-Alcoholic Steatohepatitis Market Overview

Figure 4.           Europe Non-Alcoholic Steatohepatitis Market, By Application

Figure 5.           Europe Non-Alcoholic Steatohepatitis Market, By Country

Figure 6.           Europe: PEST Analysis

Figure 7.           Europe Experts Opinion

Figure 8.           Europe Non-Alcoholic Steatohepatitis (NASH) Market Impact Analysis of Drivers and Restraints

Figure 9.           Europe Non-Alcoholic Steatohepatitis Market– Revenue Forecast and Analysis

Figure 10.        Europe Product Market Analysis and Forecast 2021 and 2028 (%)

Figure 11.        Europe Vitamin E and Pioglitazone Revenue and Forecast to 2028 (US$ Mn)

Figure 12.        Europe Ocaliva Revenue and Forecast to 2028 (US$ Mn)

Figure 13.        Europe Elafibranor Revenue and Forecast to 2028 (US$ Mn)

Figure 14.        Europe Selonsertib Revenue and Forecast to 2028 (US$ Mn)

Figure 15.        Europe Others Revenue and Forecast to 2028 (US$ Mn)

Figure 16.        Europe Application Market Analysis and Forecast 2021 and 2028 (%)

Figure 17.        Europe Treatment Market Revenue and Forecast to 2028 (US$ Mn)

Figure 18.        Europe Diagnosis Market Revenue and Forecast to 2028 (US$ Mn)

Figure 19.        Europe Sales Channel Market Analysis and Forecast 2021 and 2028 (%)

Figure 20.        Europe Hospital Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 21.        Europe Retail Pharmacy Market Revenue and Forecast to 2028 (US$ Mn)

Figure 22.        Europe Online Provider Market Revenue and Forecast to 2028 (US$ Mn)

Figure 23.        Europe: Non-alcoholic steatohepatitis (NASH) Market, by Key Country – Revenue (2021) (US$ Million)

Figure 24.        Europe: Non-alcoholic steatohepatitis (NASH) Market, by Country, 2021 & 2028 (%)

Figure 25.        Germany: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.        France: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27.        UK: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 28.        Italy: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.        Spain: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30.        Rest of Europe: Non-alcoholic steatohepatitis (NASH) Market – Revenue and Forecast to 2028 (US$ Million)